NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VOR

Vor Biopharma Inc

Jun 30 • 04:00PM ET

1.62

Dollar change +0.56
Percentage change 52.83	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY GILD MRNA REGN VRTX BLUE CRSP EDIT NTLA PFE

| Held by: VTI VXF CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	38.49%	Shs Outstand	124.85M	Perf Week	458.62%
Market Cap	202.43M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	-0.01%	Shs Float	76.86M	Perf Month	730.34%
Enterprise Value	173.18M	PEG	-	EPS next Q	-0.44	Inst Own	42.26%	Short Float	4.19%	Perf Quarter	115.17%
Income	-118.60M	P/S	-	EPS this Y	56.45%	Inst Trans	-5.65%	Short Ratio	0.24	Perf Half Y	85.25%
Sales	0.00M	P/B	3.06	EPS next Y	36.23%	ROA	-85.83%	Short Interest	3.22M	Perf YTD	45.95%
Book/sh	0.53	P/C	3.37	EPS next 5Y	21.90%	ROE	-125.43%	52W High	1.80 -10.00%	Perf Year	40.87%
Cash/sh	0.48	P/FCF	-	EPS past 3/5Y	3.38% -38.02%	ROIC	-128.09%	52W Low	0.13 1135.70%	Perf 3Y	-72.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	68.61% 27.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	15.10%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	93.81	Recom	2.60
Dividend Gr. 3/5Y	- -	Current Ratio	3.88	EPS Q/Q	42.54%	SMA20	314.95%	Beta	2.05	Target Price	4.54
Payout	-	Debt/Eq	0.47	Sales Q/Q	-	SMA50	306.11%	Rel Volume	5.37	Prev Close	1.06
Employees	159	LT Debt/Eq	0.40	Earnings	May 08	SMA200	96.54%	Avg Volume	13.42M	Price	1.62
IPO	Feb 05, 2021	Option/Short	Yes / No	EPS/Sales Surpr.	-0.76% -	Trades		Volume	67,004,200	Change	52.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Upgrade	H.C. Wainwright	Neutral → Buy	$3
Jul-26-22	Initiated	Wedbush	Outperform	$18
Apr-27-22	Initiated	Goldman	Neutral	$6
Dec-17-21	Initiated	H.C. Wainwright	Buy	$26
Dec-03-21	Initiated	Robert W. Baird	Outperform	$38
Dec-02-21	Initiated	Oppenheimer	Outperform	$30
Oct-19-21	Initiated	JMP Securities	Mkt Outperform	$40
Mar-25-21	Initiated	B. Riley Securities	Buy	$60
Mar-03-21	Initiated	Evercore ISI	Outperform	$48
Mar-03-21	Initiated	Barclays	Overweight	$56
Mar-02-21	Initiated	Stifel	Buy	$58
Mar-02-21	Initiated	Goldman	Sell	$19

Show Previous Ratings

Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks) +52.83%
Jun-26-25 11:22AM	Vor, with new CEO, changes course to target autoimmune disease (BioPharma Dive) +60.53%
02:00AM	PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement (Business Wire)
Jun-25-25 04:50PM	Vor Bio Announces $175 Million Private Placement (GlobeNewswire) +74.28%
04:45PM	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset (GlobeNewswire)
08:30AM	Loading…
May-08-25 08:30AM	Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -70.12%
Apr-30-25 02:00AM	PureTech Announces Annual Results for Year Ended December 31, 2024 (Business Wire)
Mar-20-25 05:01PM	Vor Biopharma files for $350M mixed securities shelf (SeekingAlpha)
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Feb-13-25 08:00AM	Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials (GlobeNewswire)
Feb-03-25 08:00AM	Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.63%
Jan-27-25 09:55AM	Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.12%
Jan-08-25 09:00AM	Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors (GlobeNewswire)
Dec-28-24 09:27AM	Vor Biopharma Secures $55.6M for Cancer Therapy Trials (TipRanks)
Dec-27-24 02:43PM	Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% (GuruFocus.com) +51.55%
09:00AM	Loading…
09:00AM	Vor Bio Announces $55.6 Million Private Placement (GlobeNewswire)
Dec-09-24 07:30AM	Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design (GlobeNewswire) +26.89%
Nov-12-24 08:00AM	Vor Bio to Participate in the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-07-24 04:05PM	Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire) +14.85%
Sep-30-24 07:00AM	Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer (GlobeNewswire)
Sep-06-24 02:00AM	PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies (Business Wire) +10.06%
Sep-05-24 04:01PM	New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies (GlobeNewswire)
Aug-28-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 04:05PM	Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Aug-02-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.98% -7.51%
Jul-09-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
May-13-24 09:22AM	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating (MT Newswires)
May-09-24 10:54PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024 (InvestorPlace) -5.52%
04:05PM	Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
08:00AM	Loading…
May-06-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-03-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 04:01PM	Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors (GlobeNewswire)
Apr-04-24 08:32AM	Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock (Zacks)
Apr-01-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.17%
Mar-20-24 09:53PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023 (InvestorPlace) +8.89%
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)
Mar-05-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks)
Feb-07-24 08:00AM	Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.53%
Jan-19-24 08:22AM	Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study (Zacks) -8.30%
Jan-17-24 04:01PM	Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update (GlobeNewswire) +7.39%
Dec-21-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11% -8.37%
Dec-01-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.98%
Nov-27-23 08:00AM	Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-09-23 04:01PM	Vor Bio Presents Positive Data Update on Trem-cel at HSCT Conference (GlobeNewswire) -5.38%
Nov-07-23 04:05PM	Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) +9.34% -6.53%
Nov-03-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.43%
08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 09:01AM	Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform (GlobeNewswire) +5.74%
Oct-03-23 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.63%
Sep-25-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 04:05PM	Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) +14.40%
Aug-01-23 08:00AM	Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jun-09-23 04:03PM	Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients (Benzinga) -6.19%
07:30AM	Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bios Platform (GlobeNewswire)
Jun-05-23 08:00AM	Vor Bio to Participate in the Goldman Sachs Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire)
Apr-19-23 02:42PM	We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-18-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.82%
Mar-28-23 09:55AM	How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06% (Zacks)
Mar-23-23 04:01PM	Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update (GlobeNewswire) -6.08% +15.29%
Mar-07-23 05:52AM	Vor Biopharma Inc. (NASDAQ:VOR) Shares Could Be 43% Below Their Intrinsic Value Estimate (Simply Wall St.)
Feb-21-23 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-16-23 02:04PM	Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant (Benzinga) -6.47%
12:00PM	First AML Patient Transplanted with Vor Bios Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg Cycles at Initial Dose Level (GlobeNewswire)
Jan-19-23 08:00AM	Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings (GlobeNewswire)
Jan-12-23 08:00AM	Vor Bio to Present at B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire)
Dec-16-22 06:40PM	Bath & Body Works and Vor Biopharma Stock See Action From Activist Investors (Barrons.com) -11.17%
Dec-07-22 07:45AM	Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million (GlobeNewswire) +41.86%
07:30AM	First AML Patient Successfully Transplanted with Vor Bios Investigational Trem-cel (VOR33) and Tolerated Mylotarg (GlobeNewswire)
Nov-30-22 10:35AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $15 (TipRanks) +6.48%
Nov-22-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-10-22 04:15PM	Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update (GlobeNewswire) +5.03%
Nov-01-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-14-22 10:26AM	Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely? (Simply Wall St.)
Oct-12-22 08:00AM	Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer (GlobeNewswire)
Oct-11-22 08:00AM	Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment (GlobeNewswire)
Sep-28-22 08:00AM	Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters (GlobeNewswire)
Sep-06-22 04:15PM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-01-22 09:55AM	Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-16-22 09:55AM	How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295% (Zacks)
Aug-11-22 04:15PM	Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update (GlobeNewswire) +8.43%
Aug-01-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.64%
Jun-10-22 08:00AM	Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA (GlobeNewswire)
Jun-01-22 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-22 04:15PM	Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update (GlobeNewswire)
May-07-22 09:20AM	We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth (Simply Wall St.)
May-05-22 08:00AM	Vor to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Apr-25-22 08:00AM	Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting (GlobeNewswire)
Apr-14-22 04:15PM	Vor Bio Announces Retirement of Chief Medical Officer (GlobeNewswire) +8.74%
Mar-22-22 10:10AM	Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases (Business Wire) +6.16%
Mar-14-22 04:30PM	Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update (GlobeNewswire) -9.52%
Feb-28-22 08:00AM	Vor to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-11-22 08:00AM	Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -7.03%
Jan-04-22 08:00AM	Vor to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-29-21 08:00AM	Vor to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT ANG	Officer	Jun 30 '25	Proposed Sale	1.73	40,627	70,289		Jun 30 05:15 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Feb 13 '25	Sale	1.42	2,227	3,162	126,625	Feb 18 04:20 PM
EYAL ATTAR	Officer	Feb 13 '25	Proposed Sale	1.38	2,227	3,073		Feb 13 04:32 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Feb 10 '25	Sale	1.37	2,554	3,499	128,852	Feb 12 04:29 PM
EYAL ATTAR	Officer	Feb 10 '25	Proposed Sale	1.41	2,554	3,601		Feb 10 04:34 PM
Attar Eyal C.	CHIEF MEDICAL OFFICER	Dec 27 '24	Sale	1.25	10,334	12,918	81,439	Dec 31 04:15 PM
EYAL ATTAR	Officer	Dec 27 '24	Proposed Sale	0.84	10,334	8,660		Dec 27 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VOR

Vor Biopharma Inc

Upgrade your FINVIZ experience